APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Antifibrotic Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Antifibrotic Drug Industry Research Report 2026

Report ID 173966200520 December 2025138 pages

Choose your research edition.

Industry ResearchAntifibrotic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Antifibrotic Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Antifibrotic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antifibrotic Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Antifibrotic Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Antifibrotic Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Antifibrotic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Antifibrotic Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Antifibrotic Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Antifibrotic Drug include Accord Healthcare, Amneal Pharmaceuticals, Apotex, Beacon Pharma, Boehringer Ingelheim, Eskayef Pharmaceuticals, ScieGen Pharmaceuticals, Gyre Pharmaceuticals and Kawin, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Antifibrotic Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Antifibrotic Drug Market by Company

Accord Healthcare

Amneal Pharmaceuticals

Apotex

Beacon Pharma

Boehringer Ingelheim

Eskayef Pharmaceuticals

ScieGen Pharmaceuticals

Gyre Pharmaceuticals

Kawin

Roche

Qilu Pharmaceutical

PuraCap

Sandoz

CSPC Pharmaceutical Group

Kelun Pharmaceutical

Teva

Antifibrotic Drug Segment by Type

Nintedanib

Pirfenidone

Antifibrotic Drug Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Antifibrotic Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antifibrotic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antifibrotic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antifibrotic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Antifibrotic Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Antifibrotic Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Antifibrotic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Antifibrotic Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Antifibrotic Drug Sales (k units) of Manufacturers (2021-2026) Table 7. Global Antifibrotic Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Antifibrotic Drug Revenue of Manufacturers (2021-2026) Table 9. Global Antifibrotic Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Antifibrotic Drug Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Antifibrotic Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Antifibrotic Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Antifibrotic Drug, Product Type & Application Table 14. Global Antifibrotic Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Antifibrotic Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Accord Healthcare Company Information Table 19. Accord Healthcare Business Overview Table 20. Accord Healthcare Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Accord Healthcare Antifibrotic Drug Product Portfolio Table 22. Accord Healthcare Recent Developments Table 23. Amneal Pharmaceuticals Company Information Table 24. Amneal Pharmaceuticals Business Overview Table 25. Amneal Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio Table 27. Amneal Pharmaceuticals Recent Developments Table 28. Apotex Company Information Table 29. Apotex Business Overview Table 30. Apotex Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Apotex Antifibrotic Drug Product Portfolio Table 32. Apotex Recent Developments Table 33. Beacon Pharma Company Information Table 34. Beacon Pharma Business Overview Table 35. Beacon Pharma Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Beacon Pharma Antifibrotic Drug Product Portfolio Table 37. Beacon Pharma Recent Developments Table 38. Boehringer Ingelheim Company Information Table 39. Boehringer Ingelheim Business Overview Table 40. Boehringer Ingelheim Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Boehringer Ingelheim Antifibrotic Drug Product Portfolio Table 42. Boehringer Ingelheim Recent Developments Table 43. Eskayef Pharmaceuticals Company Information Table 44. Eskayef Pharmaceuticals Business Overview Table 45. Eskayef Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio Table 47. Eskayef Pharmaceuticals Recent Developments Table 48. ScieGen Pharmaceuticals Company Information Table 49. ScieGen Pharmaceuticals Business Overview Table 50. ScieGen Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio Table 52. ScieGen Pharmaceuticals Recent Developments Table 53. Gyre Pharmaceuticals Company Information Table 54. Gyre Pharmaceuticals Business Overview Table 55. Gyre Pharmaceuticals Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio Table 57. Gyre Pharmaceuticals Recent Developments Table 58. Kawin Company Information Table 59. Kawin Business Overview Table 60. Kawin Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Kawin Antifibrotic Drug Product Portfolio Table 62. Kawin Recent Developments Table 63. Roche Company Information Table 64. Roche Business Overview Table 65. Roche Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Roche Antifibrotic Drug Product Portfolio Table 67. Roche Recent Developments Table 68. Qilu Pharmaceutical Company Information Table 69. Qilu Pharmaceutical Business Overview Table 70. Qilu Pharmaceutical Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Qilu Pharmaceutical Antifibrotic Drug Product Portfolio Table 72. Qilu Pharmaceutical Recent Developments Table 73. PuraCap Company Information Table 74. PuraCap Business Overview Table 75. PuraCap Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. PuraCap Antifibrotic Drug Product Portfolio Table 77. PuraCap Recent Developments Table 78. Sandoz Company Information Table 79. Sandoz Business Overview Table 80. Sandoz Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Sandoz Antifibrotic Drug Product Portfolio Table 82. Sandoz Recent Developments Table 83. CSPC Pharmaceutical Group Company Information Table 84. CSPC Pharmaceutical Group Business Overview Table 85. CSPC Pharmaceutical Group Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio Table 87. CSPC Pharmaceutical Group Recent Developments Table 88. Kelun Pharmaceutical Company Information Table 89. Kelun Pharmaceutical Business Overview Table 90. Kelun Pharmaceutical Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Kelun Pharmaceutical Antifibrotic Drug Product Portfolio Table 92. Kelun Pharmaceutical Recent Developments Table 93. Teva Company Information Table 94. Teva Business Overview Table 95. Teva Antifibrotic Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Teva Antifibrotic Drug Product Portfolio Table 97. Teva Recent Developments Table 98. Global Antifibrotic Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Antifibrotic Drug Sales by Region (2021-2026) & (k units) Table 100. Global Antifibrotic Drug Sales Market Share by Region (2021-2026) Table 101. Global Antifibrotic Drug Sales by Region (2027-2032) & (k units) Table 102. Global Antifibrotic Drug Sales Market Share by Region (2027-2032) Table 103. Global Antifibrotic Drug Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Antifibrotic Drug Revenue Market Share by Region (2021-2026) Table 105. Global Antifibrotic Drug Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Antifibrotic Drug Revenue Market Share by Region (2027-2032) Table 107. North America Antifibrotic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 109. North America Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 110. North America Antifibrotic Drug Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Antifibrotic Drug Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Antifibrotic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 114. Europe Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 115. Europe Antifibrotic Drug Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Antifibrotic Drug Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Antifibrotic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 119. Asia Pacific Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 120. Asia Pacific Antifibrotic Drug Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Antifibrotic Drug Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Antifibrotic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 124. South America Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 125. South America Antifibrotic Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Antifibrotic Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Antifibrotic Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Antifibrotic Drug Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa Antifibrotic Drug Sales by Country (2027-2032) & (k units) Table 130. Middle East and Africa Antifibrotic Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Antifibrotic Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Antifibrotic Drug Sales by Type (2021-2026) & (k units) Table 133. Global Antifibrotic Drug Sales by Type (2027-2032) & (k units) Table 134. Global Antifibrotic Drug Sales Market Share by Type (2021-2026) Table 135. Global Antifibrotic Drug Sales Market Share by Type (2027-2032) Table 136. Global Antifibrotic Drug Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Antifibrotic Drug Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Antifibrotic Drug Revenue Market Share by Type (2021-2026) Table 139. Global Antifibrotic Drug Revenue Market Share by Type (2027-2032) Table 140. Global Antifibrotic Drug Price by Type (2021-2026) & (US$/unit) Table 141. Global Antifibrotic Drug Price by Type (2027-2032) & (US$/unit) Table 142. Global Antifibrotic Drug Sales by Application (2021-2026) & (k units) Table 143. Global Antifibrotic Drug Sales by Application (2027-2032) & (k units) Table 144. Global Antifibrotic Drug Sales Market Share by Application (2021-2026) Table 145. Global Antifibrotic Drug Sales Market Share by Application (2027-2032) Table 146. Global Antifibrotic Drug Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Antifibrotic Drug Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Antifibrotic Drug Revenue Market Share by Application (2021-2026) Table 149. Global Antifibrotic Drug Revenue Market Share by Application (2027-2032) Table 150. Global Antifibrotic Drug Price by Application (2021-2026) & (US$/unit) Table 151. Global Antifibrotic Drug Price by Application (2027-2032) & (US$/unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Antifibrotic Drug Distributors List Table 155. Antifibrotic Drug Customers List Table 156. Antifibrotic Drug Industry Trends Table 157. Antifibrotic Drug Industry Drivers Table 158. Antifibrotic Drug Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Antifibrotic Drug Product Image Figure 5. Global Antifibrotic Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Antifibrotic Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Antifibrotic Drug Sales (2021-2032) & (k units) Figure 8. Global Antifibrotic Drug Average Price (US$/unit) & (2021-2032) Figure 9. Nintedanib Product Image Figure 10. Pirfenidone Product Image Figure 11. Hospital and Clinic Product Image Figure 12. Retail Pharmacies Product Image Figure 13. Other Product Image Figure 14. Global Antifibrotic Drug Revenue Share by Manufacturers in 2025 Figure 15. Global Manufacturers of Antifibrotic Drug, Manufacturing Sites & Headquarters Figure 16. Global Top 5 and 10 Antifibrotic Drug Players Market Share by Revenue in 2025 Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Antifibrotic Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 19. Global Antifibrotic Drug Sales by Region in 2025 Figure 20. Global Antifibrotic Drug Revenue by Region in 2025 Figure 21. North America Antifibrotic Drug Market Size by Country in 2025 Figure 22. North America Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 23. North America Antifibrotic Drug Revenue Market Share by Country (2021-2032) Figure 24. United States Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 25. Canada Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Mexico Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Antifibrotic Drug Market Size by Country in 2025 Figure 28. Europe Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 29. Europe Antifibrotic Drug Revenue Market Share by Country (2021-2032) Figure 30. Germany Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Russia Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Spain Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Netherlands Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Switzerland Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Sweden Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Poland Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Asia Pacific Antifibrotic Drug Market Size by Country in 2025 Figure 41. Asia Pacific Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 42. Asia Pacific Antifibrotic Drug Revenue Market Share by Country (2021-2032) Figure 43. China Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Japan Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. South Korea Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. India Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Australia Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Taiwan Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Southeast Asia Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. South America Antifibrotic Drug Market Size by Country in 2025 Figure 52. South America Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 53. South America Antifibrotic Drug Revenue Market Share by Country (2021-2032) Figure 54. Brazil Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Argentina Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Chile Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Middle East and Africa Antifibrotic Drug Market Size by Country in 2025 Figure 58. Middle East and Africa Antifibrotic Drug Sales Market Share by Country (2021-2032) Figure 59. Middle East and Africa Antifibrotic Drug Revenue Market Share by Country (2021-2032) Figure 60. Egypt Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. South Africa Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Israel Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Türkiye Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. GCC Countries Antifibrotic Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Global Antifibrotic Drug Sales Market Share by Type (2021-2032) Figure 66. Global Antifibrotic Drug Revenue Market Share by Type (2021-2032) Figure 67. Global Antifibrotic Drug Price (US$/unit) by Type (2021-2032) Figure 68. Global Antifibrotic Drug Sales Market Share by Application (2021-2032) Figure 69. Global Antifibrotic Drug Revenue Market Share by Application (2021-2032) Figure 70. Global Antifibrotic Drug Price (US$/unit) by Application (2021-2032) Figure 71. Antifibrotic Drug Value Chain Figure 72. Antifibrotic Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Antifibrotic Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • Nintedanib
  • Pirfenidone
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Accord Healthcare
  • Amneal Pharmaceuticals
  • Apotex
  • Beacon Pharma
  • Boehringer Ingelheim
  • Eskayef Pharmaceuticals
  • ScieGen Pharmaceuticals
  • Gyre Pharmaceuticals
  • Kawin
  • Roche
  • Qilu Pharmaceutical
  • PuraCap
  • Sandoz
  • CSPC Pharmaceutical Group
  • Kelun Pharmaceutical
  • Teva

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Antifibrotic Drug Market Size (2021-2032)
  4. 2.2.2 Global Antifibrotic Drug Sales (2021-2032)
  5. 2.2.3 Global Antifibrotic Drug Market Average Price (2021-2032)
  6. 2.3 Antifibrotic Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Nintedanib
  9. 2.3.3 Pirfenidone
  10. 2.4 Antifibrotic Drug by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Hospital and Clinic
  13. 2.4.3 Retail Pharmacies
  14. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Antifibrotic Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Antifibrotic Drug Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Antifibrotic Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Antifibrotic Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Antifibrotic Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Antifibrotic Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Antifibrotic Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Antifibrotic Drug, Established Date
  9. 3.9 Global Antifibrotic Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Accord Healthcare
  2. 4.1.1 Accord Healthcare Company Information
  3. 4.1.2 Accord Healthcare Business Overview
  4. 4.1.3 Accord Healthcare Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Accord Healthcare Antifibrotic Drug Product Portfolio
  6. 4.1.5 Accord Healthcare Recent Developments
  7. 4.2 Amneal Pharmaceuticals
  8. 4.2.1 Amneal Pharmaceuticals Company Information
  9. 4.2.2 Amneal Pharmaceuticals Business Overview
  10. 4.2.3 Amneal Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amneal Pharmaceuticals Antifibrotic Drug Product Portfolio
  12. 4.2.5 Amneal Pharmaceuticals Recent Developments
  13. 4.3 Apotex
  14. 4.3.1 Apotex Company Information
  15. 4.3.2 Apotex Business Overview
  16. 4.3.3 Apotex Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Apotex Antifibrotic Drug Product Portfolio
  18. 4.3.5 Apotex Recent Developments
  19. 4.4 Beacon Pharma
  20. 4.4.1 Beacon Pharma Company Information
  21. 4.4.2 Beacon Pharma Business Overview
  22. 4.4.3 Beacon Pharma Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Beacon Pharma Antifibrotic Drug Product Portfolio
  24. 4.4.5 Beacon Pharma Recent Developments
  25. 4.5 Boehringer Ingelheim
  26. 4.5.1 Boehringer Ingelheim Company Information
  27. 4.5.2 Boehringer Ingelheim Business Overview
  28. 4.5.3 Boehringer Ingelheim Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Boehringer Ingelheim Antifibrotic Drug Product Portfolio
  30. 4.5.5 Boehringer Ingelheim Recent Developments
  31. 4.6 Eskayef Pharmaceuticals
  32. 4.6.1 Eskayef Pharmaceuticals Company Information
  33. 4.6.2 Eskayef Pharmaceuticals Business Overview
  34. 4.6.3 Eskayef Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Eskayef Pharmaceuticals Antifibrotic Drug Product Portfolio
  36. 4.6.5 Eskayef Pharmaceuticals Recent Developments
  37. 4.7 ScieGen Pharmaceuticals
  38. 4.7.1 ScieGen Pharmaceuticals Company Information
  39. 4.7.2 ScieGen Pharmaceuticals Business Overview
  40. 4.7.3 ScieGen Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 ScieGen Pharmaceuticals Antifibrotic Drug Product Portfolio
  42. 4.7.5 ScieGen Pharmaceuticals Recent Developments
  43. 4.8 Gyre Pharmaceuticals
  44. 4.8.1 Gyre Pharmaceuticals Company Information
  45. 4.8.2 Gyre Pharmaceuticals Business Overview
  46. 4.8.3 Gyre Pharmaceuticals Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Gyre Pharmaceuticals Antifibrotic Drug Product Portfolio
  48. 4.8.5 Gyre Pharmaceuticals Recent Developments
  49. 4.9 Kawin
  50. 4.9.1 Kawin Company Information
  51. 4.9.2 Kawin Business Overview
  52. 4.9.3 Kawin Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Kawin Antifibrotic Drug Product Portfolio
  54. 4.9.5 Kawin Recent Developments
  55. 4.10 Roche
  56. 4.10.1 Roche Company Information
  57. 4.10.2 Roche Business Overview
  58. 4.10.3 Roche Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Roche Antifibrotic Drug Product Portfolio
  60. 4.10.5 Roche Recent Developments
  61. 4.11 Qilu Pharmaceutical
  62. 4.11.1 Qilu Pharmaceutical Company Information
  63. 4.11.2 Qilu Pharmaceutical Business Overview
  64. 4.11.3 Qilu Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Qilu Pharmaceutical Antifibrotic Drug Product Portfolio
  66. 4.11.5 Qilu Pharmaceutical Recent Developments
  67. 4.12 PuraCap
  68. 4.12.1 PuraCap Company Information
  69. 4.12.2 PuraCap Business Overview
  70. 4.12.3 PuraCap Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 PuraCap Antifibrotic Drug Product Portfolio
  72. 4.12.5 PuraCap Recent Developments
  73. 4.13 Sandoz
  74. 4.13.1 Sandoz Company Information
  75. 4.13.2 Sandoz Business Overview
  76. 4.13.3 Sandoz Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sandoz Antifibrotic Drug Product Portfolio
  78. 4.13.5 Sandoz Recent Developments
  79. 4.14 CSPC Pharmaceutical Group
  80. 4.14.1 CSPC Pharmaceutical Group Company Information
  81. 4.14.2 CSPC Pharmaceutical Group Business Overview
  82. 4.14.3 CSPC Pharmaceutical Group Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 CSPC Pharmaceutical Group Antifibrotic Drug Product Portfolio
  84. 4.14.5 CSPC Pharmaceutical Group Recent Developments
  85. 4.15 Kelun Pharmaceutical
  86. 4.15.1 Kelun Pharmaceutical Company Information
  87. 4.15.2 Kelun Pharmaceutical Business Overview
  88. 4.15.3 Kelun Pharmaceutical Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Kelun Pharmaceutical Antifibrotic Drug Product Portfolio
  90. 4.15.5 Kelun Pharmaceutical Recent Developments
  91. 4.16 Teva
  92. 4.16.1 Teva Company Information
  93. 4.16.2 Teva Business Overview
  94. 4.16.3 Teva Antifibrotic Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Teva Antifibrotic Drug Product Portfolio
  96. 4.16.5 Teva Recent Developments
5 Global Antifibrotic Drug Market Scenario by Region
  1. 5.1 Global Antifibrotic Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Antifibrotic Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Antifibrotic Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Antifibrotic Drug Sales by Region: 2027-2032
  5. 5.3 Global Antifibrotic Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Antifibrotic Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Antifibrotic Drug Revenue by Region: 2027-2032
  8. 5.4 North America Antifibrotic Drug Market Facts & Figures by Country
  9. 5.4.1 North America Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Antifibrotic Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Antifibrotic Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Antifibrotic Drug Market Facts & Figures by Country
  16. 5.5.1 Europe Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Antifibrotic Drug Sales by Country (2021-2032)
  18. 5.5.3 Europe Antifibrotic Drug Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Antifibrotic Drug Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Antifibrotic Drug Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Antifibrotic Drug Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Antifibrotic Drug Market Facts & Figures by Country
  41. 5.7.1 South America Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Antifibrotic Drug Sales by Country (2021-2032)
  43. 5.7.3 South America Antifibrotic Drug Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Antifibrotic Drug Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Antifibrotic Drug Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Antifibrotic Drug Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Antifibrotic Drug Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Antifibrotic Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Antifibrotic Drug Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Antifibrotic Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Antifibrotic Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Antifibrotic Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Antifibrotic Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Antifibrotic Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Antifibrotic Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Antifibrotic Drug Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Antifibrotic Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Antifibrotic Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Antifibrotic Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Antifibrotic Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Antifibrotic Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Antifibrotic Drug Value Chain Analysis
  2. 8.1.1 Antifibrotic Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Antifibrotic Drug Production Mode & Process
  5. 8.2 Antifibrotic Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Antifibrotic Drug Distributors
  8. 8.2.3 Antifibrotic Drug Customers
9 Global Antifibrotic Drug Analyzing Market Dynamics
  1. 9.1 Antifibrotic Drug Industry Trends
  2. 9.2 Antifibrotic Drug Industry Drivers
  3. 9.3 Antifibrotic Drug Industry Opportunities and Challenges
  4. 9.4 Antifibrotic Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst